Catalyst Pharmaceutical CPRX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $149.39M+5.6% | $152.61M+7.6% | $148.39M+15.3% | $146.56M+19.4% | $141.42M+43.6% | ||
| $14.48M-19.2% | $26.07M+20.5% | $22.65M+17.5% | $20.61M+33.8% | $17.91M+43.1% | ||
| $134.92M+9.2% | $126.54M+5.3% | $125.74M+14.9% | $125.95M+17.4% | $123.51M+43.6% | ||
| 90.3%+3.0pp | 82.9%-1.8pp | 84.7%-0.3pp | 85.9%-1.5pp | 87.3%0.0pp | ||
| $2.66M-31.5% | $1.81M-52.4% | $2.66M-19.1% | $4.36M+46.0% | $3.89M+50.6% | ||
| $49.32M+5.1% | $53.42M+20.9% | $47.47M+3.5% | $45.95M+12.8% | $46.91M-0.1% | ||
| $73.23M+15.6% | $61.85M-1.6% | $66.27M+30.2% | $66.3M+22.2% | $63.37M+134% | ||
| 49%+4.2pp | 40.5%-3.8pp | 44.7%+5.1pp | 45.2%+1.0pp | 44.8%+17.3pp | ||
| $11M+38.9% | $10.06M-11.3% | $4.77M-24.3% | $3M+94.2% | $7.92M+303% | ||
| $84.23M+18.2% | $71.9M-3.1% | $71.04M+24.2% | $69.29M+24.2% | $71.29M+145% | ||
| $20.5M+40.9% | $19.2M+5.3% | $18.25M+37.0% | $17.19M+14.6% | $14.55M+150% | ||
| $63.73M+12.3% | $52.7M-5.8% | $52.78M+20.3% | $52.11M+27.7% | $56.74M+144% | ||
| 42.7%+2.5pp | 34.5%-4.9pp | 35.6%+1.5pp | 35.6%+2.3pp | 40.1%+16.5pp | ||
| $0.50+11.1% | $0.41-6.8% | $0.42+20.0% | $0.41+24.2% | $0.45+137% | ||
| $0.52+10.6% | $0.43-6.5% | $0.43+16.2% | $0.43+22.9% | $0.47+135% | ||
| 126.9M0.0% | 127.3M+1.9% | 127.1M+1.3% | 127.5M+2.3% | 127M+2.9% | ||
| 122.3M+0.6% | 122.3M+3.2% | 122.6M+3.1% | 122.2M+3.4% | 121.5M+4.0% | ||
| $9.7M+3.8% | $9.47M+1.3% | $9.34M0.0% | $9.34M0.0% | $9.35M0.0% | ||
| $63.74M+12.5% | $52.7M-5.9% | $52.75M+20.2% | $52.16M+27.9% | $56.66M+144% | ||
| $76.16M-2.4% | $90.77M+14.9% | $82.13M+5.6% | $80.27M+17.2% | $78.05M+9.3% | ||
| $8K+110% | $0-100% | -$31K— | $48K— | -$81K-479% | ||
| $11M+38.9% | $10.06M-11.3% | $4.77M-24.3% | $3M+94.2% | $7.92M+303% | ||
| $149.39M+5.6% | $152.61M+7.6% | $148.39M+15.3% | $146.56M+19.4% | $141.42M+43.6% | ||
| $73.23M+15.6% | $61.85M-1.6% | $66.27M+30.2% | $66.3M+22.2% | $63.37M+134% | ||
| $83.01M+14.0% | $71.38M-1.3% | $75.68M+25.4% | $75.76M+19.0% | $72.83M+99.2% | ||
| $83.01M+14.0% | $71.38M-1.3% | $75.68M+25.4% | $75.76M+19.0% | $72.83M+99.2% | ||
| 55.6%+4.1pp | 46.8%-4.2pp | 51%+4.1pp | 51.7%-0.2pp | 51.5%+14.4pp | ||
| $73.23M+15.6% | $61.85M-1.6% | $66.27M+30.2% | $66.3M+22.2% | $63.37M+134% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Catalyst Pharmaceutical's revenue?
- Catalyst Pharmaceutical (CPRX) generated $597.0M in revenue over the trailing twelve months, up 11.7% year over year.
- Is Catalyst Pharmaceutical profitable?
- Catalyst Pharmaceutical reported $221.3M in net income over the trailing twelve months, a 37.1% net margin.
- What are Catalyst Pharmaceutical's profit margins?
- Gross margin is 86.0% and operating margin is 44.8%, with a 37.1% net margin.
- What is Catalyst Pharmaceutical's earnings per share?
- Catalyst Pharmaceutical's diluted EPS over the trailing twelve months is $1.74.
- Where does Catalyst Pharmaceutical's income statement data come from?
- Every line is extracted from Catalyst Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
